Table 3 Promising vaccine formulations for the treatment of viral infections
From: Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines
Lipid(s) and sterol used | Virus type | Cell line/animal model used | Administration route | Promising liposome formulation | References |
|---|---|---|---|---|---|
DOTMA | Hepatitis C | HepG2 cells and BALB/c mice | Transcutaneous | DOTMA | [85] |
DC-Chol | Hepatitis B | Lymph node cells, BALB/c, OF1 and B10.M mice | Subcutaneous | DC-Chol | [84] |
DMPC, DMPC/DMPG, DC-Chol/DOPE, DSTAP/Chol, DDA/Chol, DOTAP/Chol, DMTAP/Chol and CCS/Chol | Influenza H3N2 | Splenocytes from BALB/c and C57BL/6 mice | Intranasal | DMTAP/Chol and DOTAP/Chol | [45] |
DDA | Respiratory Syncytial Virus | BALB/c mice | Intranasal | DDA | [88] |
DOPC/OPPE (Influenza virosome) and DOPC/OPPE (liposomes) | Influenza | MDMs, MDDCs, 16HBE14o cells, PHNECs and EPCam + cells | N/A | DOPC/OPPE (Influenza virosome) | [86] |